|
JAK3
|
Janus kinase 3 |
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by ALK
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-9 signaling
- Interleukin-2 signaling
- Interleukin-21 signaling
- Interleukin receptor SHC signaling
- Potential therapeutics for SARS
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- R-348
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Fostamatinib
- Abrocitinib
- Zanubrutinib
|
- T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
|
|
MAL
|
mal, T cell differentiation protein (MAL blood group) |
|
|
|
|
MAP3K8
|
mitogen-activated protein kinase kinase kinase 8 |
- CD28 dependent PI3K/Akt signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
|
|
|
MIP
|
major intrinsic protein of lens fiber |
- Passive transport by Aquaporins
|
|
|
|
MS4A1
|
membrane spanning 4-domains A1 |
|
- Rituximab
- Ibritumomab tiuxetan
- Tositumomab
- Ofatumumab
- Obinutuzumab
- Technetium Tc-99m nofetumomab merpentan
- Ublituximab
- Ocrelizumab
- Mosunetuzumab
- Odronextamab
|
|
|
NCOA6
|
nuclear receptor coactivator 6 |
- BMAL1:CLOCK,NPAS2 activates circadian expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Cytoprotection by HMOX1
- Heme signaling
- Formation of WDR5-containing histone-modifying complexes
- Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
|
|
|
NSMAF
|
neutral sphingomyelinase activation associated factor |
- TNFR1-mediated ceramide production
|
|
|
|
PIK3R1
|
phosphoinositide-3-kinase regulatory subunit 1 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Signaling by ALK
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- GP1b-IX-V activation signalling
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- RET signaling
- RHOA GTPase cycle
- Extra-nuclear estrogen signaling
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- RHOF GTPase cycle
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- RND3 GTPase cycle
- RND2 GTPase cycle
- RND1 GTPase cycle
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK in cancer
- Signaling by LTK
- Co-stimulation by ICOS
|
- SF1126
- Enzastaurin
- Wortmannin
|
|
|
PLP1
|
proteolipid protein 1 |
|
|
- Hypomyelinating leukodystrophy (HLD); Pelizaeus-Merzbacher disease (PMD)
- Hereditary spastic paraplegia (SPG)
|
|
RIPK2
|
receptor interacting serine/threonine kinase 2 |
- NOD1/2 Signaling Pathway
- NOD1/2 Signaling Pathway
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Ovarian tumor domain proteases
- Interleukin-1 signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
|
|
|
|
SLC30A2
|
solute carrier family 30 member 2 |
- Zinc efflux and compartmentalization by the SLC30 family
|
|
|
|
SLC30A3
|
solute carrier family 30 member 3 |
- Zinc efflux and compartmentalization by the SLC30 family
|
|
|
|
SLC39A13
|
solute carrier family 39 member 13 |
|
|
- Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
|
|
SLC61A1
|
solute carrier family 61 member 1 |
|
|
|
|
SLC7A1
|
solute carrier family 7 member 1 |
- Amino acid transport across the plasma membrane
|
- Lysine
- Arginine
- Ornithine
|
|
|
TANK
|
TRAF family member associated NFKB activator |
- TICAM1-dependent activation of IRF3/IRF7
- TRAF6 mediated IRF7 activation
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
- Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
|
|
|
|
TDP2
|
tyrosyl-DNA phosphodiesterase 2 |
- Nonhomologous End-Joining (NHEJ)
|
|
|
|
TLCD1
|
TLC domain containing 1 |
|
|
|
|
TMEM107
|
transmembrane protein 107 |
|
|
|
|
TMEM128
|
transmembrane protein 128 |
|
|
|